Participated · Series B · Apr 2020

Scopio Labs has launched an AI-based Complete Blood Morphology (CBM) analyzer designed to fully automate blood morphology diagnostics. The CBM uses Scopio’s Full-Field technology, combining advanced imaging and AI to analyze ten times more cells than current methods. The product targets the global laboratory staffing crisis by standardizing and automating peripheral blood smear (PBS) reviews and potentially eliminating routine human reviews. Scopio holds CE-marked and FDA-cleared digital imaging applications and plans to showcase the CBM at the ADLM 2025 Annual Conference. Viola Growth invested an additional $10 million to support the CBM’s market launch, raising Scopio’s Series D to $52 million. Company leadership says the technology could reshape hematology workflows, economics, and enable development of morphology-based biomarkers for earlier detection and monitoring of disease. Scopio Labs develops Full-Field Digital Cell Morphology imaging and analysis platforms that use computational photography to capture high-resolution images of thousands of cells. Its platform pairs full-field imaging with clinical AI-based decision support to improve workflow efficiency, enable remote consultation, and expedite diagnostic decision-making in blood cell analysis. The technology is intended to supplant manual microscopy by providing a full-field view of all regions of clinical interest at high resolution. Scopio says it will use new capital to accelerate market penetration, scale sales and marketing, and strengthen customer support globally. The company also plans continued development of its digital morphology platform and creation of next-generation products for hematology laboratories and hospitals. Financially, Scopio recently closed a $42 million Series D, bringing its total fundraising to $130 million. Scopio Labs develops a digital microscopy platform that captures and digitizes full-slide microscopy data using advanced computational photography to reconstruct high-resolution images. Its automated scanning systems deliver high-quality images and include computer-vision based decision support for hematology, pathology, research and veterinary use. The company has launched ScopioVet, an end-to-end digital cytology solution for veterinary professionals. Scopio recently received CE mark certification for its X100 Full Field Peripheral Blood Smear (PBS) system, an all-in-one automated in-vitro hematology diagnostic platform that enables remote consultation. A multi-center study in preparation for an FDA submission is being completed. Led by co-founder and CEO Itai Hayut, the company plans to expand commercial operations across the United States and Europe, ramp up manufacturing and sales, and build a stronger clinical trial pipeline to broaden its offerings. Scopio Labs develops next-generation digital microscopes based on computational imaging breakthroughs and a suite of dedicated image analysis tools. Its technology targets clinical and research applications including cancer, hematology, cytology, academic research and drug discovery. The company was founded in 2015 by Itai Hayut and Erez Na’aman. Scopio plans to use the new funding to expand its Tel Aviv–based team and is hiring computer vision experts, physicists and software developers. The article frames the company as enabling dramatic clinical and research improvements and powering further innovation in diagnostics and discovery.

Participated · Equity · Jun 2017

Highcon is a Yavne, Israel–based creator of a digital cutting and creasing solution for the post-print market. Its core products use patented Digital Adhesive Rule Technology to create crease lines, alongside laser solutions for cutting and etching, introducing automation into finishing. The systems target traditional print applications such as packaging, greeting cards, folders, and large-format display items, enabling printers and packaging converters to offer differentiated services. Since launching at drupa 2012, the company has installed more than 50 machines worldwide. Highcon raised $20m in new funding in a round led by Jerusalem Venture Partners, with participation from existing investors Landa Ventures, LR Group, OurCrowd and Go Capital. The company will use the funds to expand global reach and continue product development of its digital finishing solutions. Highcon builds digital finishing machinery based on its patented DART (Digital Adhesive Rule Technology), most notably the Highcon Euclid and the upgraded Euclid II. The Euclid family converts cutting and creasing from an analogue to a digital workflow, enabling faster turnaround, lower costs, shorter run lengths and a reduced carbon footprint. The company emphasizes partnerships and pilots with customers such as American Greetings, Gafs Cartong, Skitza, Xeicon and Minolta to expand international presence. Founded in November 2009 and headquartered in Yavne, Israel, Highcon is led by co‑founders Aviv Ratzman and Michael Zimmer and counts industry pioneer Benny Landa as a large shareholder and strategic advisor. Since OurCrowd's initial investment in November 2013, Highcon reported that revenue more than doubled from 2013 to 2014. The company cites a large addressable market (the $82B folding carton segment within a $312B packaging market) and highlights the Euclid II's lower entry price and upgradability as drivers of future adoption.